MK-8189
Total Payments
$17.2M
Transactions
1,343
Doctors
41
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $486,666 | 112 | 9 |
| 2019 | $182,868 | 18 | 2 |
| 2018 | $4.3M | 214 | 0 |
| 2017 | $12.3M | 999 | 35 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $17.1M | 1,021 | 99.4% |
| Consulting Fee | $69,400 | 26 | 0.4% |
| Travel and Lodging | $27,880 | 102 | 0.2% |
| Food and Beverage | $10,916 | 194 | 0.1% |
Payments by Type
Research
$17.1M
1,021 transactions
General
$108,196
322 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia. | Merck Sharp & Dohme Corporation | $16.0M | 1 |
| A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics andPharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients | Merck Sharp & Dohme Corporation | $382,314 | 0 |
| A Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia | Merck Sharp & Dohme Corporation | $298,192 | 0 |
| A Two-Period Study to Evaluate the Effects of Multiple Oral Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-8189 in Healthy Subjects. | Merck Sharp & Dohme Corporation | $200,218 | 0 |
| A 2-Part Randomized Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Alternate MK-8189 Titration Regimens in Young Adult Participants With Schizophrenia and to Evaluate the Safety, Tolerability and Pharmacokinetics of MK 8189 in Elderly Participants With Schizophrenia | Merck Sharp & Dohme Corporation | $171,711 | 0 |
| A multiple-dose clinical study to evaluate the safety, tolerability,pharmacokinetics and QTc effect of MK-8189 in participants with schizophrenia and healthy participants | Merck Sharp & Dohme Corporation | $112,912 | 0 |
| A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in combination with Pembrolizumab in Patients with Advanced Malignancies | Merck Sharp & Dohme Corporation | $259.05 | 0 |
Top Doctors Receiving Payments for MK-8189
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| David Miller | — | Philadelphia, PA | $17.1M | 1,022 |
| , M.D | Psychiatry | Indianapolis, IN | $19,552 | 19 |
| , MD | Neurology | Philadelphia, PA | $5,675 | 2 |
| , MD | Neurology | Los Angeles, CA | $5,675 | 2 |
| , MD | Geriatric Psychiatry | Rochester, NY | $5,008 | 4 |
| , MD | Psychiatry | Little Rock, AR | $4,966 | 9 |
| , MD | Geriatric Psychiatry | Seattle, WA | $4,825 | 2 |
| , MD | Clinical Neurophysiology | Phoenix, AZ | $4,825 | 2 |
| , M.D | Psychiatry | Baltimore, MD | $4,275 | 2 |
| , MD | Psychiatry | Los Angeles, CA | $4,275 | 2 |
| John Kane | Psychiatry | Glen Oaks, NY | $2,250 | 2 |
| , M.D | Psychiatry | New York, NY | $2,063 | 1 |
| , M.D | Research Study | Rockville, MD | $1,881 | 11 |
| , MD | Psychiatry | Barling, AR | $1,822 | 11 |
| , M.D | Psychiatry | Dayton, OH | $1,681 | 10 |
| , M.D | Psychiatry | Austin, TX | $1,636 | 15 |
| , MD | Public Health & General Preventive Medicine | Dayton, OH | $1,635 | 12 |
| , M.D | Psychiatry | Saint Louis, MO | $1,634 | 12 |
| , MD | Psychiatry | Los Angeles, CA | $1,625 | 2 |
| , M.D | Psychiatry | Cerritos, CA | $1,611 | 12 |
| , M.D | Psychiatry | San Diego, CA | $1,535 | 10 |
| , M.D | Psychiatry | Costa Mesa, CA | $1,511 | 12 |
| , M.D., PH.D | Neurology | Washington, DC | $1,500 | 1 |
| , MD | Psychiatry | Jamaica, NY | $1,476 | 12 |
| , MD | Psychiatry | Dallas, TX | $1,463 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $17.2M
- Total Doctors 41
- Transactions 1,343
About MK-8189
MK-8189 is a drug associated with $17.2M in payments to 41 healthcare providers, recorded across 1,343 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $486,666 was paid across 112 transactions to 9 doctors.
The most common payment nature for MK-8189 is "Unspecified" ($17.1M, 99.4% of total).
MK-8189 is associated with 7 research studies, including "A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 using Risperidone as Active Control in Subjects Experiencing an AcuteEpisode of Schizophrenia." ($16.0M).